
Alina M Allen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6412111/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies. Clinical Gastroenterology and Hepatology, 2015, 13, 643-654.e9.	2.4	1,199
2	Advancing the global public health agenda for NAFLD: a consensus statement. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 60-78.	8.2	330
3	Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 yearâ€community study. Hepatology, 2018, 67, 1726-1736.	3.6	239
4	Sarcopenia in hiding: The risk and consequence of underestimating muscle dysfunction in nonalcoholic steatohepatitis. Hepatology, 2017, 66, 2055-2065.	3.6	196
5	The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity – A longitudinal cohort study. Journal of Hepatology, 2019, 71, 1229-1236.	1.8	181
6	Chronic kidney disease and associated mortality after liver transplantation – A time-dependent analysis using measured glomerular filtration rate. Journal of Hepatology, 2014, 61, 286-292.	1.8	141
7	Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network metaâ€analysis. Hepatology, 2015, 62, 1417-1432.	3.6	139
8	Time trends in the health care burden and mortality of acute on chronic liver failure in the United States. Hepatology, 2016, 64, 2165-2172.	3.6	138
9	Diabetes Is Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Cirrhosis From Nonalcoholic Fatty Liver Disease. Hepatology, 2020, 71, 907-916.	3.6	123
10	Hepatocellular Carcinoma Is the Most Common Indication for Liver Transplantation and Placement on the Waitlist in the United States. Clinical Gastroenterology and Hepatology, 2017, 15, 767-775.e3.	2.4	112
11	Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases. Hepatology, 2022, 75, 219-228.	3.6	107
12	Healthcare Cost and Utilization in Nonalcoholic Fatty Liver Disease: Realâ€World Data From a Large U.S. Claims Database. Hepatology, 2018, 68, 2230-2238.	3.6	103
13	Reduced Access to Liver Transplantation in Women: Role of Height, MELD Exception Scores, and Renal Function Underestimation. Transplantation, 2018, 102, 1710-1716.	0.5	103
14	Administrative Coding in Electronic Health Care Recordâ€Based Research of NAFLD: An Expert Panel Consensus Statement. Hepatology, 2021, 74, 474-482.	3.6	102
15	Recurrent or De Novo Allograft Steatosis and Long-term Outcomes After Liver Transplantation. Transplantation, 2019, 103, e14-e21.	0.5	77
16	The Role of Threeâ€Dimensional Magnetic Resonance Elastography in the Diagnosis of Nonalcoholic Steatohepatitis in Obese Patients Undergoing Bariatric Surgery. Hepatology, 2020, 71, 510-521.	3.6	65
17	The Epidemiology of Liver Diseases Unique to Pregnancy inÂaÂUSÂCommunity: A Population-Based Study. Clinical Gastroenterology and Hepatology, 2016, 14, 287-294.e2.	2.4	64
18	Liver Stiffness by Magnetic Resonance Elastography Predicts Future Cirrhosis, Decompensation, and Death in NAFLD. Clinical Gastroenterology and Hepatology, 2021, 19, 1915-1924.e6.	2.4	57

Alina M Allen

#	Article	IF	CITATIONS
19	Natural History of Nonalcoholic Fatty Liver Disease With Normal Body Mass Index: A Population-Based Study. Clinical Gastroenterology and Hepatology, 2022, 20, 1374-1381.e6.	2.4	43
20	AGA Clinical Practice Guideline on the Management of Coagulation Disorders in Patients With Cirrhosis. Gastroenterology, 2021, 161, 1615-1627.e1.	0.6	43
21	Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design. Journal of Hepatology, 2022, 77, 1237-1245.	1.8	40
22	Serum Cystatin C as an Indicator of Renal Function and Mortality in Liver Transplant Recipients. Transplantation, 2015, 99, 1431-1435.	0.5	37
23	Comparative Expression of Renin-Angiotensin Pathway Proteins in Visceral Versus Subcutaneous Fat. Frontiers in Physiology, 2018, 9, 1370.	1.3	37
24	Women With Nonalcoholic Fatty Liver Disease Lose Protection Against Cardiovascular Disease: A Longitudinal Cohort Study. American Journal of Gastroenterology, 2019, 114, 1764-1771.	0.2	34
25	Multiparametric Magnetic Resonance Elastography Improves the Detection of NASH Regression Following Bariatric Surgery. Hepatology Communications, 2020, 4, 185-192.	2.0	26
26	Magnetic resonance elastography for prediction of longâ€ŧerm progression and outcome in chronic liver disease: A retrospective study. Hepatology, 2022, 75, 379-390.	3.6	26
27	Epidemiology and Healthcare Burden of Acute-on-Chronic Liver Failure. Seminars in Liver Disease, 2016, 36, 123-126.	1.8	22
28	Nonalcoholic fatty liver. Current Opinion in Organ Transplantation, 2016, 21, 99-106.	0.8	20
29	Chronic Intermittent Hypoxia Triggers a Senescence-like Phenotype in Human White Preadipocytes. Scientific Reports, 2020, 10, 6846.	1.6	19
30	Circulating extracellular vesicles are a biomarker for NAFLD resolution and response to weight loss surgery. Nanomedicine: Nanotechnology, Biology, and Medicine, 2021, 36, 102430.	1.7	19
31	Development of the Al-Cirrhosis-ECG Score: An Electrocardiogram-Based Deep Learning Model in Cirrhosis. American Journal of Gastroenterology, 2022, 117, 424-432.	0.2	17
32	Automated Analysis of Multiparametric Magnetic Resonance Imaging/Magnetic Resonance Elastography Exams for Prediction of Nonalcoholic Steatohepatitis. Journal of Magnetic Resonance Imaging, 2021, 54, 122-131.	1.9	16
33	Change in serial liver stiffness measurement by magnetic resonance elastography and outcomes in NAFLD. Hepatology, 2023, 77, 268-274.	3.6	16
34	Efficacy and Safety of Treatment of Hepatitis C in Patients With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2013, 11, 1655-1660.e1.	2.4	15
35	The Role of Magnetic Resonance Elastography in the Diagnosis of Noncirrhotic Portal Hypertension. Clinical Gastroenterology and Hepatology, 2020, 18, 3051-3053.e2.	2.4	14
36	AGA Technical Review on Coagulation in Cirrhosis. Gastroenterology, 2021, 161, 1630-1656.	0.6	14

Alina M Allen

#	Article	lF	CITATIONS
37	A Cohort Study Examining the Interaction of Alcohol Consumption and Obesity in Hepatic Steatosis and Mortality. Mayo Clinic Proceedings, 2020, 95, 2612-2620.	1.4	12
38	Liver stiffness measurement by magnetic resonance elastography is not affected by hepatic steatosis. European Radiology, 2022, 32, 950-958.	2.3	11
39	Liver biopsy in the real world—reporting, expert concordance and correlation with a pragmatic clinical diagnosis. Alimentary Pharmacology and Therapeutics, 2021, 54, 1472-1480.	1.9	10
40	Association between Visceral Adipose Tissue and Non-Alcoholic Steatohepatitis Histology in Patients with Known or Suspected Non-Alcoholic Fatty Liver Disease. Journal of Clinical Medicine, 2021, 10, 2565.	1.0	7
41	Familial Hypobetalipoproteinemia: An Underrecognized Cause of Lean NASH. Hepatology, 2021, 74, 2897-2898.	3.6	7
42	Longitudinal Changes in MR Elastography–based Biomarkers in Obese Patients Treated with Bariatric Surgery. Clinical Gastroenterology and Hepatology, 2023, 21, 220-222.e3.	2.4	5
43	Extrahepatic Malignancies in Nonalcoholic Fatty Liver Disease. Current Hepatology Reports, 2019, 18, 455-472.	0.4	4
44	Relationship Between Body Mass Index and Survival Among Critically Ill Patients With Cirrhosis. Journal of Intensive Care Medicine, 2022, 37, 817-824.	1.3	4
45	Reply to: "Chronic kidney disease (CKD) and NAFLD: Time for awareness and screening― Journal of Hepatology, 2015, 62, 984-985.	1.8	2
46	The Importance of Glycemic Equipoise in NASH. Hepatology, 2021, 74, 1145-1147.	3.6	2
47	Characterizing specific subgroups in patients with NAFLD: overweight vs obese phenotype. Revista Espanola De Enfermedades Digestivas, 2019, 111, 253-255.	0.1	1
48	Reply to: "Chronic kidney disease after liver transplantation― Journal of Hepatology, 2015, 62, 244-245.	1.8	0
49	Reply:. Hepatology, 2019, 70, 1493-1494.	3.6	0
50	Increasing nonalcoholic steatohepatitis overlap in liver transplant recipients: Additive risk for de novo malignancy. Clinical Transplantation, 2022, , e14714.	0.8	0